CD19 and diffuse large B-cell lymphoma: In addition, preliminary findings from an ongoing phase IIb study (NCT02030834) evaluating the safety and efficacy of the anti-CD19 CAR-T cells in patients with relapsed or refractory DLBCL and follicular lymphoma showed an ORR of 50 %, a CR of 45 % and a PFS of 37 % at median follow up 6 months with acceptable toxicity in the 12 evaluable patients with relapsed or refractory DLBCL (Additional file 1: Table S8) [461].